We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Benign Hematology

Journal Scan / Research · March 24, 2021

Comorbidities and Malignancies Negatively Affect Survival in Myelodysplastic Syndromes

Blood advances

 

Additional Info

Blood advances
Comorbidities and Malignancies Negatively Affect Survival in Myelodysplastic Syndromes: A Population-Based Study
Blood Adv 2021 Mar 09;5(5)1344-1351, J Rozema, M Hoogendoorn, R Kibbelaar, E van den Berg, N Veeger, E van Roon

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading